In studies examining the mechanism of anti-metastatic action, we observed that ISLA treatment almost completely blocked PMA-induced MAPK activation and inhibited nuclear translocation of the NF-κB p65 subunit, resulting in decreased MMP activity, which is crucial for cancer metastasis (Figures 1, 4). The gene discussed is NFKB1; the disease is cancer.